Armata Pharmaceuticals Announces Structural Biology Publication

Core Insights - Armata Pharmaceuticals has published a paper detailing the structure of phage Pa193, a key candidate for its multi-phage anti-Pseudomonas clinical products [1][2] - The research enhances understanding of phage structure and function, potentially expanding clinical applications beyond Pseudomonas aeruginosa [3] Company Overview - Armata Pharmaceuticals is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections [4] - The company is advancing a pipeline of natural and synthetic phage candidates targeting various pathogens, including Pseudomonas aeruginosa and Staphylococcus aureus [4]